Discovery of AMP mimetics that exhibit high inhibitory potency and specificity for AMP deaminase

Journal of the American Chemical Society

Volumn 121, Issue 2, 1999, Pages 308-319

  Erion, Mark D ^a   Kasibhatla, Srinivas Rao ^a   Bookser, Brett C ^a   Van Poelje, Paul D ^a   Reddy, M Rami ^a   Gruber, Harry E ^a   Appleman, James R ^a  

^a Metabasis Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; ADENOSINE MONOPHOSPHATE DEAMINASE; ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; COFORMYCIN; DIAZEPINE DERIVATIVE; ENZYME INHIBITOR; PROTECTIVE AGENT;

ANIMAL CELL; ARTICLE; BRAIN PROTECTION; DRUG DESIGN; DRUG POTENCY; ENZYME BINDING; ENZYME INHIBITION; ENZYME SPECIFICITY; HEART PROTECTION; INHIBITION KINETICS; NONHUMAN; RAT;

EID: 0033585527     PISSN: 00027863     EISSN: None     Source Type: Journal    
DOI: 10.1021/ja983153j     Document Type: Article

References (91)

1. (a) Jacobson, K. A.; Kim, Y. C.; Wildman, S. S.; Mohanram, A.; Harden, T. K.; Boyer, J. L.; King, B. F.; Burnstock, G. J. Med. Chem. 1998, 41, 2201-2206.
2. (b) Jianguo, G. G.; MacDermott, A. B. Nature 1997, 389, 749-753.
3. Mittal, R.; Ahmadian, M. R.; Goody, R. S.; Wittinghofer, A. Science 1996, 273, 115-117.
4. (a) Escalante, C. R.; Yie, L.; Thanos, D.; Aggarwal, A. K. Nature 1998, 391, 103-106.
5. (b) Levitzki, A.; Gazit, A. Science 1995, 267, 1782-1788.
6. (a) Norman, T. C.; Gray, N. S.; Koh, J. T.; Schultz, P. G. J. Am. Chem. Soc. 1996, 118, 7430-7431.
7. (b) Tong, L.; Pav, S.; White, D. M.; Rogers, S.; Crane, K. M.; Cywin, C. L.; Brown, M. L.; Pargellis, C. A. Nat. Struct. Biol. 1997, 4, 311-316.
8. (a) Hardie, D. G. Nature 1994, 370, 599-600.
9. (b) Corton, J. M.; Gillespie, J. G.; Hardie, D. G. Curr. Biol. 1994, 4, 315-324.
10. (c) Moore, F.; Weekes, J.; Hardie, D. G. Eur. J. Biochem. 1991, 199, 691-697.
11. In addition to having decreased electrostatic interactions, most nucleotide mimetics with decreased negative charge use groups that are structurally dissimilar to phosphate based on geometry, anionic charge, and molecular size. In a few cases, modest binding affinity is retained. For example, a series of cyclic dicarboxylic acids have replaced the phosphate of cyclic guanosine 3′,5′-monophosphate with micromolar inhibitor potencies: Tulshian, D.; Czarniecki, M.; Doll, R. J.; Ahn, H.-S. J. Med. Chem. 1993, 36, 1210-1220.
12. For example, see structures of: (a) glycogen phosphorylase b: Sprang, S. R.; Withers, S. G.; Goldsmith, E. J.; Fletterick, R. J.; Madsen, N. B. Science 1991, 254, 1367-1371. (b) Phosphofructokinase: Schirmer, T.; Evans, P. R. Nature 1990, 343, 140-145. (c) Fructose 1,6-bisphosphatase: Ke, H.; Liang, J.; Zhang, Y.; Lipscomb, W. N. Biochemistry 1991, 30, 4412-4420. (d) Adenylate kinase: Schultz, G. E.; Elzinga, M.; Marx, F.; Schirmer, R. H. Nature 1974, 250, 120-123.
13. For example, see structures of: (a) glycogen phosphorylase b: Sprang, S. R.; Withers, S. G.; Goldsmith, E. J.; Fletterick, R. J.; Madsen, N. B. Science 1991, 254, 1367-1371. (b) Phosphofructokinase: Schirmer, T.; Evans, P. R. Nature 1990, 343, 140-145. (c) Fructose 1,6-bisphosphatase: Ke, H.; Liang, J.; Zhang, Y.; Lipscomb, W. N. Biochemistry 1991, 30, 4412-4420. (d) Adenylate kinase: Schultz, G. E.; Elzinga, M.; Marx, F.; Schirmer, R. H. Nature 1974, 250, 120-123.
14. For example, see structures of: (a) glycogen phosphorylase b: Sprang, S. R.; Withers, S. G.; Goldsmith, E. J.; Fletterick, R. J.; Madsen, N. B. Science 1991, 254, 1367-1371. (b) Phosphofructokinase: Schirmer, T.; Evans, P. R. Nature 1990, 343, 140-145. (c) Fructose 1,6-bisphosphatase: Ke, H.; Liang, J.; Zhang, Y.; Lipscomb, W. N. Biochemistry 1991, 30, 4412-4420. (d) Adenylate kinase: Schultz, G. E.; Elzinga, M.; Marx, F.; Schirmer, R. H. Nature 1974, 250, 120-123.
15. For example, see structures of: (a) glycogen phosphorylase b: Sprang, S. R.; Withers, S. G.; Goldsmith, E. J.; Fletterick, R. J.; Madsen, N. B. Science 1991, 254, 1367-1371. (b) Phosphofructokinase: Schirmer, T.; Evans, P. R. Nature 1990, 343, 140-145. (c) Fructose 1,6-bisphosphatase: Ke, H.; Liang, J.; Zhang, Y.; Lipscomb, W. N. Biochemistry 1991, 30, 4412-4420. (d) Adenylate kinase: Schultz, G. E.; Elzinga, M.; Marx, F.; Schirmer, R. H. Nature 1974, 250, 120-123.
16. (a) Zielke, C. L.; Suelter, C. H. J. Biol. Chem. 1971, 246, 1313-1317.
17. (b) Lowenstein, J. M. Physiol. Rev. 1972, 52, 382-414.
18. (c) Bontemps, F.; Van den Berghe, G.; Hers, H. G. J. Clin. Invest. 1986, 77, 824-830.
19. The first AMPDA inhibitors were neither potent nor cell penetrable. Hampton, A.; Sasaki, T.; Perini, F.; Slotin, L. A.; Kappler, F. J. Med. Chem. 1976, 19, 1029-1033.
20. (a) Webster, H. K.; Whaun, J. M.; Walker, M. D.; Bean, T. L. Biochem. Pharmacol. 1984, 33, 1555-1557.
21. (b) Zielke, C. L.; Suelter, C. H. In The Enzymes, 3rd ed.; Boyer, P. D., Ed.; Academic Press: New York, 1971; Vol. IV, pp 72-73.
22. (a) Gruber, H. E. U.S. Patent 4,912,092, 1990.
23. (b) Erion, M. D.; Bookser, B. C., Kasibhatla, S. R. U.S. Patent 5,731,432, 1998.
24. (a) Jacobson, K. A.; van Galen, P. J. M.; Williams, M. J. Med. Chem. 1992, 35, 407-422.
25. (b) Erion, M. D. Annu. Rep. Med. Chem. 1993, 28, 295-304.
26. (a) Chen, W.; Hoerter, J.; Gueron, M. J. Mol. Cell. Cardiol. 1996, 28, 2163-2174.
27. (b) Chen, W.; Gueron, M. J. Mol. Cell. Cardiol. 1996, 28, 2175-2182.
28. Tagetmeyer, H. J. Mol. Cell. Cardiol. 1985, 17, 1013-1018.
29. Loh, E.; Rebbeck, R. R.; Mahoney, P. D.; Stolle, C. A.; Swain, J. L.; Holmes, E. W. Circulation 1996, 94, (Suppl. 1) 2534.
30. Wolfenden, R. Acc. Chem. Res. 1972, 5, 10-18.
31. (a) Wolfenden, R.; Wentworth, D. F.; Mitchell, G. N. Biochemistry 1969, 16, 5071-5077.
32. (b) Evans, B. E.; Wolfenden, R. Biochemistry 1973, 12, 392-397.
33. (c) Kurz, L. C.; Frieden, C. Biochemistry 1983, 22, 382-389.
34. (d) Kurz, L. C.; Frieden, C. Biochemistry 1987, 26, 8450-8457.
35. (e) Weiss, P. M.; Cook, P. F.; Hermes, J. D.; Cleland, W. W. Biochemistry 1987, 26, 6, 7378-7384.
36. (a) Merkler, D. J.; Schramm, V. L. Biochemistry 1993, 32, 5792-5799.
37. (b) Merkler, D. J.; Kline, P. C.; Weiss, P.; Schramm, V. L. Biochemistry 1993, 32, 12993-13001.
38. (c) Bagdassarian, C. K.; Schramm, V. L.; Schwartz, S. D. J. Am. Chem. Soc. 1996, 118, 8825-8836.
39. (a) Wilson, D. K.; Rudolph, F. B.; Quiocho, F. A. Science 1991, 252, 1278-1284.
40. (b) Sharff, A. J.; Wilson, D. K.; Chang, Z.; Quiocho, F. A. J. Mol. Biol. 1992, 226, 917-921.
41. (c) Wilson, D. K.; Quiocho, F. A. Biochemistry 1993, 32, 1689-1694.
42. (d) Wilson, D. K.; Quiocho, F. A. Struct. Biol. 1994, 1, 691-694.
43. (a) Kati, W. M.; Wolfenden, R. Science 1989, 243, 1591-1593.
44. (b) Kati, W. M.; Wolfenden, R. Biochemistry 1989, 28, 7919-7927.
45. (c) Jones, W.; Kurz, L. C.; Wolfenden, R. Biochemistry 1989, 28, 1242-1247.
46. (d) Jones, W.; Wolfenden, R. J. Am. Chem. Soc. 1986, 108, 7444-7445.
47. (a) Sabina, R. L.; Morisaki, T.; Clarke, P.; Eddy, R.; Shows, T. B.; Morton, C. C.; Holmes, E. W. J. Biol. Chem. 1990, 265, 9423-9433.
48. (b) Morisaki, T.; Sabina, R. L.; Holmes, E. W. J. Biol. Chem. 1990, 265, 11482-11486.
49. (c) Mahnke-Zizelman, D. K.; Sabina, R. L.; J. Biol. Chem. 1992, 267, 20866-20877.
50. Yeung, C. Y.; Ingolia, D. E.; Roth, D. B.; Shoemaker, C.; Al-Ubaidi, M. R.; Yen, J. Y.; Ching, C.; Bobonis, C.; Kaufman, R. J.; Kellems, R. E. J. Biol. Chem. 1985, 260, 10299-10307.
51. Sequence alignment compared murine ADA with human E-, L-, and M-AMPDA isoenzymes.
52. (a) Agarwal, R. P.; Spector, T.; Parks, R. E., Jr. Biochem. Pharmacol. 1977, 26, 359-367.
53. (b) Radzicka, A.; Wolfenden, R. Methods Enzymol. 1995, 249, 284-312.
54. (c) Bzowska, A.; Lassota, P.; Shugar, D. Z. Naturforsch. 1985, 40c, 710-714.
55. Frieden, C.; Kurz, L. C.; Gilbert, H. R. Biochemistry 1980, 19, 5303-5309.
56. Merkler, D. J.; Brenowitz, M.; Schramm, V. L. Biochemistry 1990, 29, 8358-8364.
57. (a) Kati, W. M.; Acheson, S. A.; Wolfenden, R. Biochemistry 1992, 31, 7356-7366.
58. (b) Wolfenden, R.; Wentworth, D. F.; Mitchell, G. N. Biochemistry 1977, 16, 5071-5077. Similarly, interactions outside of the base binding region were important for cytidine deaminase, see: Carlow, D. C.; Short, S. A.; Wolfenden, R. Biochemistry 1998, 37, 1199-1203.
59. (b) Wolfenden, R.; Wentworth, D. F.; Mitchell, G. N. Biochemistry 1977, 16, 5071-5077. Similarly, interactions outside of the base binding region were important for cytidine deaminase, see: Carlow, D. C.; Short, S. A.; Wolfenden, R. Biochemistry 1998, 37, 1199-1203.
60. Erion, M. D.; Reddy, M. R. J. Comput. Chem. 1995, 12, 1513-1521.
61. Erion, M. D.; Reddy, M. R. J. Am. Chem. Soc. 1998, 120, 3295-3304.
62. 1 = 3 μM (Table 1). (a) Agarwal, R. P.; Parks, R. E., Jr. Biochem. Pharmacol. 1977, 26, 663-666. (b) Merkler, D. J.; Schramm, V. L. J. Biol. Chem. 1990, 265, 4420-4426.
63. 1 = 3 μM (Table 1). (a) Agarwal, R. P.; Parks, R. E., Jr. Biochem. Pharmacol. 1977, 26, 663-666. (b) Merkler, D. J.; Schramm, V. L. J. Biol. Chem. 1990, 265, 4420-4426.
64. Kredich, N. M.; Hershfield, M. S. In The Metabolic Basis of Inherited Disease, 6th ed.; Scrivner, C. R., Eds.; McGraw-Hill: New York, 1989; pp 1045-1075.
65. Chan, E.; Putt, S. R.; Showalter, H. D. H.; Baker, D. C. J. Org. Chem. 1982, 47, 3457-3464.
66. Bookser, B. C.; Kasibhatla, S. R.; Appleman, J. R.; Erion, M. D., unpublished results.
67. Guida, W. C.; Bohacek, R S.; Erion, M. D. J. Comput. Chem. 1992, 13, 214-228.
68. Kasibhatla, S. R.; Bookser, B. C.; Appleman, J. R.; Probst, G.; Xiao, W.; Erion, M. D., unpublished results.
69. Boger, D. L.; Mullican, M. D. Org. Synth. 1987, 65, 98-107.
70. Echavarren, A. M.; Stille, J. K. J. Am. Chem. Soc. 1987, 109, 5478-5486.
71. Tautz, W.; Teitel, S.; Brossi, A. J. Med. Chem. 1973, 16, 705-707.
72. 3.
73. 1H NMR showed showed trace amounts of the debrominated product (<5%).
74. (a) Van den Berghe, G.; Bontemps, M. F.; Van den Berghe, F. Prog. Neurobiol. 1992, 39, 547-561.
75. (b) Skladanowski, A. C. In Myocardial Energy Metabolism; de Jong, J. W., Ed.; Martinus Nijhoff Publishers: Boston, 1988; pp 53-65.
76. Van den Berghe, G.; Bontemps, F.; Hers, G.-G. Biochem. J. 1980, 188, 913-920.
77. (a) Erion, M. D.; Niwas, S.; Rose, J. D.; Ananthan, S.; Allen, M.; Secrist, J. A., III; Babu, Y. S.; Bugg, C. E.; Guida, W. C.; Ealick, S. E.; Montgomery, J. A. J. Med. Chem. 1993, 36, 3771-3783.
78. (b) Ealick, S. E.; Babu, Y. S.; Bugg, C. S.; Erion, M. D.; Guida, W. C.; Montgomery J. A.; Secrist, J. A., III. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 11540-11544.
79. (a) Erion, M. D.; Takabayshi, K.; Smith, H. B.; Kessi, J.; Wagner, S.; Honig, S.; Shames, S. L.; Ealick, S. E. Biochemistry 1997, 36, 11725-11734.
80. (b) Erion, M. D.; Guida, W. C.; Stoeckler, J. D.; Ealick, S. E. Biochemistry 1997, 36, 11735-11748.
81. (c) Stoeckler, J. D.; Poirot, A. F.; Smith, R. M.; Parks, R. E., Jr.; Ealick, S. E.; Takabayashi, K.; Erion, M. D. Biochemistry 1997, 36, 11749-11756.
82. (a) Ingwall, J. S. Circulation 1993, 87, (Suppl. VII), 58-62.
83. (b) Nascimben, L.; Friedrich, J.; Liao, R.; Pauletto, P.; Pessina, A.; Ingwall, J. S. Circulation 1995, 91, 1824-1833.
84. (c) Scheuer, J. Circulation 1993, 87, (Suppl. VII), 54-57.
85. (a) Appleman, J. R.; Erion, M. D. Expert Opin. Invest. Drugs 1998, 7, 225-243.
86. (b) Williams, M. Drug Dev. Res. 1993, 28, 438-444.
87. The 8R-coformycin aglycon analogue was prepared previously with minimal characterization: (a) Smal, E., Ph.D. Thesis, University of Alabama, 1985. (b) Al-Razzak, L. A.; Bendetti, A. E.; Waugh, W. N.; Stella, V. J. Pharm. Res. 1990, 7, 452.
88. The 8R-coformycin aglycon analogue was prepared previously with minimal characterization: (a) Smal, E., Ph.D. Thesis, University of Alabama, 1985. (b) Al-Razzak, L. A.; Bendetti, A. E.; Waugh, W. N.; Stella, V. J. Pharm. Res. 1990, 7, 452.
89. Smiley, K. L., Jr.; Berry, A. J.; Suelter, C. H. J. Biol. Chem. 1967, 242, 2502-2506.
90. Berry, M. N.; Friend, D. S. J. Cell. Biol. 1969, 43, 506-520.
91. Woods, H. F. Biochem. J. 1970, 119, 501-510.